Biomaterials and Bioactive Agents in Spinal Fusion

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Spinal Surgery

Background:

• Spinal fusion (SF) is crucial for stabilizing degenerative spine pathologies.
• Autologous bone graft (ABG) is the gold standard, but limitations drive research into bone graft substitutes.
• Developing effective de novo bone formation and solid fusion remains a significant clinical challenge.

Purpose of the Study:

• To review recent literature on novel approaches for consistent bone fusion in spinal vertebrae.
• To analyze new biomaterials, growth factor (GF) delivery, and cell-based therapies for spinal fusion.
• To evaluate the potential of innovative delivery platforms for bone fusion enhancement.

Main Methods:

• Literature review of recent studies on spinal fusion biomaterials and biologics.
• Analysis of polyesters (e.g., polycaprolactone, polylactic acid) as composite platforms.
• Evaluation of mesenchymal stem cells and growth factors (e.g., BMP-2, NELL-1) for bone formation.

Main Results:

• Polyester composites with mineral elements, cells, or GFs show promising fusion outcomes in animal models.
• Growth factor delivery, particularly BMP-2, yields favorable results, though burst release and dosing require further research.
• Cell-based therapies, including genetically engineered mesenchymal stem cells, have shown inconsistent fusion efficacy.

Conclusions:

• Advanced biomaterials and controlled growth factor delivery systems are nearing clinical application for spinal fusion.
• These novel approaches offer potential for high fusion performance with improved cost and safety profiles.
• Further research is needed to understand cell behavior and optimize cell-based therapies for consistent spinal fusion outcomes.